JP2022040140A5 - - Google Patents

Info

Publication number

JP2022040140A5

JP2022040140A5 JP2021205350A JP2021205350A JP2022040140A5 JP 2022040140 A5 JP2022040140 A5 JP 2022040140A5 JP 2021205350 A JP2021205350 A JP 2021205350A JP 2021205350 A JP2021205350 A JP 2021205350A JP 2022040140 A5 JP2022040140 A5 JP 2022040140A5

Authority

JP

Japan

Prior art keywords

population

cells

retinal

preparation according

preparation

Prior art date

2021-12-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002360 preparation method Methods 0.000 claims 23
• 210000004027 cell Anatomy 0.000 claims 15
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 14
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims 10
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 7
• 239000008121 dextrose Substances 0.000 claims 7
• 239000011780 sodium chloride Substances 0.000 claims 7
• 201000007737 Retinal degeneration Diseases 0.000 claims 5
• 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 4
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 4
• 239000001509 sodium citrate Substances 0.000 claims 4
• 208000017442 Retinal disease Diseases 0.000 claims 3
• 206010012601 diabetes mellitus Diseases 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 150000004687 hexahydrates Chemical class 0.000 claims 3
• 230000004258 retinal degeneration Effects 0.000 claims 3
• 206010018325 Congenital glaucomas Diseases 0.000 claims 2
• 206010010541 Congenital melanosis Diseases 0.000 claims 2
• 206010012565 Developmental glaucoma Diseases 0.000 claims 2
• 208000004453 Retinal Dysplasia Diseases 0.000 claims 2
• 206010038848 Retinal detachment Diseases 0.000 claims 2
• 206010038910 Retinitis Diseases 0.000 claims 2
• 208000001309 degenerative myopia Diseases 0.000 claims 2
• 230000004340 degenerative myopia Effects 0.000 claims 2
• 150000004683 dihydrates Chemical class 0.000 claims 2
• 208000037805 labour Diseases 0.000 claims 2
• 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
• 210000000608 photoreceptor cell Anatomy 0.000 claims 2
• 229920000642 polymer Polymers 0.000 claims 2
• 239000002243 precursor Substances 0.000 claims 2
• 230000004264 retinal detachment Effects 0.000 claims 2
• 229960000999 sodium citrate dihydrate Drugs 0.000 claims 2
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
• OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 claims 1
• 206010062328 Congenital cyst Diseases 0.000 claims 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
• 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
• 238000002659 cell therapy Methods 0.000 claims 1
• 238000005138 cryopreservation Methods 0.000 claims 1
• 230000007850 degeneration Effects 0.000 claims 1
• 238000007865 diluting Methods 0.000 claims 1
• 230000003394 haemopoietic effect Effects 0.000 claims 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
• 229920002674 hyaluronan Polymers 0.000 claims 1
• 229960003160 hyaluronic acid Drugs 0.000 claims 1
• 210000005036 nerve Anatomy 0.000 claims 1
• 210000001178 neural stem cell Anatomy 0.000 claims 1
• 230000002207 retinal effect Effects 0.000 claims 1
• 210000003994 retinal ganglion cell Anatomy 0.000 claims 1
• 150000003839 salts Chemical class 0.000 claims 1
• 239000001632 sodium acetate Substances 0.000 claims 1
• 235000017281 sodium acetate Nutrition 0.000 claims 1
• 229940010747 sodium hyaluronate Drugs 0.000 claims 1
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
• 239000012453 solvate Substances 0.000 claims 1